New Drug For Seriously Ill COVID-19 Patients Shows Promise Under Right To Try Act

New information collected under the federal Right to Try Act shows promise for the new drug ZYESAMI, now in clinical trials for the treatment of serious cases of COVID-19. The information was collected by a hospital in the U.S. southwest, drug developer NRx announced in a news release Jan. 26. ZYESAMI, developed by the Radnor, Pennsylvania-based pharmaceuticals company, currently is being tested with patients as part of the approval process of the U.S. Food and Drug Administration (FDA). The company hopes to earn emergency-use authorization (EUA) that would allow widespread use of the drug in the treatment of COVID-19. For now, the drug has progressed far enough in the process to be used by more patients under the federal Right to Try Act. That law allows the use of investigational drugs for patients diagnosed with life-threatening diseases or conditions, who have tried all approved treatment options, and who cannot participate …  » Read full article